Impact of post-transplant TKIs on long-term outcomes of allo-HSCT in ALL

Ivan Moiseev, MD, PhD, First Saint Petersburg State Medical University, Saint Petersburg, Russia, touches on the impact of post-transplant tyrosine kinase inhibitor (TKI) administration on long-term outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL) patients. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).